Drug Detail:Sonidegib (Sonidegib [ soe-ni-deg-ib ])
Drug Class: Hedgehog pathway inhibitors
Sonidegib Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the clinical use of sonidegib during breastfeeding. Because sonidegib is 97% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 28 days and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during sonidegib therapy.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Sonidegib
CAS Registry Number
956697-53-3
Drug Class
-
Breast Feeding
-
Lactation
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Hedgehog Pathway Inhibitors
-
Signal Transduction Inhibitors
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Drug Levels and Effects
- Substance Identification